, Tracking Stock Market Picks
Enter Symbol:
Caladrius Biosciences Inc. (CLBS) [hlAlert]

down 75.84 %

NEOSTEM INC. (NBS) rated Buy with price target $23 by Aegis Capital

Posted on: Thursday,  Jan 2, 2014  11:25 AM ET by Aegis Capital

Aegis Capital rated Buy Caladrius Biosciences Inc. (NASDAQ: CLBS) on 01/02/2014. Previously Aegis Capital rated Buy Caladrius Biosciences Inc. (NASDAQ: CLBS) on
06/24/2013., when the stock price was $5.30. Since then, Caladrius Biosciences Inc. has lost 75.85% as of 01/08/2016's recent price of $1.28.
If you would have followed the previous Aegis Capital's recommendation on CLBS, you would have lost 75.84% of your investment in 928 days.

NeoStem, Inc. (NeoStem) is engaged in a platform business of operating a commercial autologous (donor and recipient are the same) adult stem cell bank and in pre-disease collection, processing and long-term storage of stem cells from adult donors that they can access for their own future medical treatment. The Company manages a network of adult stem cell collection centers throughout the United States. It also entered the research and development arenas, through the acquisition of a worldwide license to an early-stage technology to identify and isolate rare stem cells from adult human bone marrow, called VSEL (very small embryonic-like) stem cells. VSELs have many physical characteristics typically found in embryonic stem cells, including the ability to differentiate into specialized cells found in substantially all the different types of cells and tissue that make up the body. In October 2009, NeoStem, Inc. completed the acquisition of China Biopharmaceuticals Holdings, Inc.

Aegis Capital
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/2/2014 11:25 AM Buy
7.32 23.00
as of 1/1/0001
1 Week   
1 Month   
3 Months   
1 YTD   
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
6/24/2013 9:25 AM Buy
5.30 25.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy